<!DOCTYPE html>
<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>input-it</title>
</head>
<body><div id="lawcontent">
<div id="preface">
<!--531.215.311--><p class="srnummer">531.215.311</p>
<h1 class="erlasstitel botschafttitel">Ordinanza del DEFR<br>concernente la costituzione di scorte obbligatorie<br>di medicamenti</h1>
<p class="erlassdatum man-space-before-3">del 20 maggio 2019 (Stato 15 gennaio 2026)</p>
</div>
<div id="preamble"><div>
<p class="man-template-autor man-space-before-10">Il Dipartimento federale dell’economia, della formazione e della ricerca (DEFR),</p>
<p class="ingress man-space-before-3">visto l’articolo 4 capoverso 1 dell’ordinanza del 10 maggio 2017<sup><a href="#fn-d16725e22" id="fnbck-d16725e22">1</a></sup> concernente la costituzione di scorte obbligatorie di medicamenti,</p>
<p class="man-template-verb man-space-before-3 man-space-after-18">ordina:</p>
<div class="footnotes"><p id="fn-d16725e22"><sup><a href="#fnbck-d16725e22">1</a></sup><sup></sup> <a href="https://fedlex.data.admin.ch/vocabulary/legal-taxonomy/7698" target="_blank" data-rs-uri="https://fedlex.data.admin.ch/eli/cc/2017/312" data-rs="531.215.31" data-lang="it">RS <b>531.215.31</b></a></p></div>
</div></div>
<main id="maintext"><article id="art_1"><a name="a1"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_1"><b>Art. 1</b> Scorte obbligatorie</a>
</h6>
<div class="collapseable"><p class="absatz man-space-before-4">Le merci menzionate nell’allegato 1 sottostanno alla costituzione di scorte obbligatorie.</p></div></article><article id="art_2"><a name="a2"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_2"><b>Art. 2</b> Esonero dall’obbligo del contratto</a>
</h6>
<div class="collapseable"><p class="absatz man-space-before-4">L’Ufficio federale per l’approvvigionamento economico del Paese (UFAE) può esonerare dall’obbligo di concludere un contratto le persone soggette all’obbligo di costituire scorte (art. 2 cpv. 3 dell’O del 10 mag. 2017 concernente la costituzione di scorte obbligatorie di medicamenti) che si impegnano, per anno civile, a immettere in commercio quantitativi inferiori a quelli menzionati nell’allegato 2.</p></div></article><article id="art_3"><a name="a3"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_3"><b>Art. 3</b> Qualità delle merci depositate </a>
</h6>
<div class="collapseable"><p class="absatz man-space-before-4">La qualità delle merci depositate rispetta sempre le norme della legislazione federale sui medicamenti e i dispositivi medici.</p></div></article><article id="art_4"><a name="a4"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_4"><b>Art. 4</b> Volume delle scorte obbligatorie di antinfettivi per uso umano</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4"><sup>1</sup> Il quantitativo totale delle merci depositate di cui all’allegato 1 numero 1 copre il fabbisogno medio della popolazione svizzera per 3 mesi.</p>
<p class="absatz man-space-before-4"><sup>1bis</sup> Per le immunoglobuline umane normali (J06BA) il quantitativo totale delle merci depositate copre il fabbisogno medio della popolazione svizzera per 2 mesi.<sup><a href="#fn-d16725e79" id="fnbck-d16725e79">2</a></sup></p>
<p class="absatz man-space-before-4"><sup>2</sup> Le scorte delle merci di cui all’allegato 1 numero 1 sono pronte all’uso. La quota delle forme galeniche e dei dosaggi corrisponde a quella dei quantitativi immessi in commercio. </p>
<p class="absatz man-space-before-4"><sup>3</sup> Il quantitativo totale dei principi attivi antinfettivi da depositare di cui all’allegato 1 numero 2 è il seguente:</p>
<dl class="man-space-after-0">
<dt class="man-space-before-4">a. </dt>
<dd class="man-space-before-4">doxiciclina: 730 kg;</dd>
<dt class="man-space-before-4">b. </dt>
<dd class="man-space-before-4">ceftriaxone: 2650 kg;</dd>
<dt class="man-space-before-4">c. </dt>
<dd class="man-space-before-4">gentamicina: 1300 kg.</dd>
</dl>
<div class="footnotes"><p id="fn-d16725e79"><sup><a href="#fnbck-d16725e79">2</a></sup><sup></sup> Introdotto dalla cifra I dell’O del DEFR del 4 dic. 2019, in vigore dal 15 gen. 2020  (<a href="https://fedlex.data.admin.ch/eli/oc/2019/782" target="_blank">RU <b>2019</b> 4759</a>).</p></div>
</div></article><article id="art_5"><a name="a5"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_5"><b>Art. 5</b> Volume delle scorte obbligatorie di inibitori della neuraminidasi della medicina umana</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4">Il quantitativo totale degli inibitori della neuraminidasi di cui all’allegato 1 numero 3 è il seguente:</p>
<dl class="man-space-after-0">
<dt class="man-space-before-4">a. </dt>
<dd class="man-space-before-4">Tamiflu®, 75 mg: 23 000 000 capsule;</dd>
<dt class="man-space-before-4">b. </dt>
<dd class="man-space-before-4">Tamiflu®, 45 mg: 850 000 capsule;</dd>
<dt class="man-space-before-4">c. </dt>
<dd class="man-space-before-4">Tamiflu®, 30 mg: 3 000 000 capsule; </dd>
<dt class="man-space-before-4">d. </dt>
<dd class="man-space-before-4">Oseltamivir: 1300 kg.</dd>
</dl>
</div></article><article id="art_6"><a name="a6"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_6"><b>Art. 6</b> Volume delle scorte obbligatorie di analgesici, vaccini e medicamenti oncologici della medicina umana</a><sup><a href="#fn-d16725e151" id="fnbck-d16725e151">3</a></sup>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4"><sup>1</sup> Il quantitativo totale dei seguenti prodotti di cui all’allegato 1 numeri 4–5<i>a</i> copre il fabbisogno medio della popolazione svizzera per la durata indicata:</p>
<dl class="man-space-after-0">
<dt class="man-space-before-4">a. </dt>
<dd class="man-space-before-4">analgesici: 3 mesi;</dd>
<dt class="man-space-before-4">b. </dt>
<dd class="man-space-before-4">vaccini: 4 mesi;</dd>
<dt class="man-space-before-4">c. </dt>
<dd class="man-space-before-4">medicamenti oncologici: 3 mesi.<sup><a href="#fn-d16725e189" id="fnbck-d16725e189">4</a></sup>
</dd>
</dl>
<p class="absatz man-space-before-4"><sup>2</sup> Le merci sono depositate pronte all’uso. La quota delle forme galeniche e dei dosaggi corrisponde a quella dei quantitativi immessi in commercio.</p>
<div class="footnotes">
<p id="fn-d16725e151"><sup><a href="#fnbck-d16725e151">3</a></sup><sup></sup> Nuovo testo giusta la cifra I dell’O del DEFR del 24 nov. 2023, in vigore dal  15 gen. 2024 (<a href="https://fedlex.data.admin.ch/eli/oc/2023/801" target="_blank">RU <b>2023</b> 801</a>).</p>
<p id="fn-d16725e189"><sup><a href="#fnbck-d16725e189">4</a></sup><sup></sup> Nuovo testo giusta la cifra I dell’O del DEFR del 24 nov. 2023, in vigore dal  15 gen. 2024 (<a href="https://fedlex.data.admin.ch/eli/oc/2023/801" target="_blank">RU <b>2023</b> 801</a>).</p>
</div>
</div></article><article id="art_6_a"><a name="a6a"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_6_a"><b>Art. 6</b><i>a</i></a><sup><a href="#fn-d16725e212" id="fnbck-d16725e212">5</a></sup><a href="#art_6_a"><i></i> <i></i>Volume delle scorte obbligatorie di altri medicamenti per la medicina umana</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4"><sup>1</sup> Il quantitativo totale delle merci depositate di cui all’allegato 1 numero 5<i>b</i> copre il fabbisogno medio della popolazione svizzera per tre mesi.<sup><a href="#fn-d16725e238" id="fnbck-d16725e238">6</a></sup></p>
<p class="absatz man-space-before-4"><sup>2</sup> Le merci sono depositate pronte all’uso. La quota delle forme galeniche e dei dosaggi corrisponde a quella dei quantitativi immessi in commercio.</p>
<div class="footnotes">
<p id="fn-d16725e212"><sup><a href="#fnbck-d16725e212">5</a></sup><sup></sup> Introdotto dalla cifra I dell’O del DEFR del 4 dic. 2019, in vigore dal 15 gen. 2020  (<a href="https://fedlex.data.admin.ch/eli/oc/2019/782" target="_blank">RU <b>2019</b> 4759</a>).</p>
<p id="fn-d16725e238"><sup><a href="#fnbck-d16725e238">6</a></sup><sup></sup> Nuovo testo giusta la cifra I dell’O del DEFR del 24 nov. 2023, in vigore dal  15 gen. 2024 (<a href="https://fedlex.data.admin.ch/eli/oc/2023/801" target="_blank">RU <b>2023</b> 801</a>).</p>
</div>
</div></article><article id="art_7"><a name="a7"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_7"><b>Art. 7</b> Volume delle scorte obbligatorie di antinfettivi della medicina veterinaria</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4"><sup>1</sup> Il quantitativo totale delle merci depositate di cui all’allegato 1 numero 6 copre il fabbisogno medio di antinfettivi per due mesi.</p>
<p class="absatz man-space-before-4"><sup>2</sup> Le merci sono depositate pronte all’uso o come principi attivi.</p>
</div></article><article id="art_8"><a name="a8"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_8"><b>Art. 8</b> Deposito delle merci sotto forma di principi attivi</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4"><sup>1</sup> Previa consultazione della cooperativa Helvecura (Helvecura) l’UFAE può concordare con gli assoggettati all’obbligo di costituire scorte che fabbricano interamente i loro prodotti in Svizzera la possibilità di depositare le merci sotto forma di principi attivi.<sup><a href="#fn-d16725e281" id="fnbck-d16725e281">7</a></sup></p>
<p class="absatz man-space-before-4"><sup>2</sup> Gli assoggettati all’obbligo di costituire scorte devono dimostrare che i principi attivi possono essere direttamente trasformati sul territorio svizzero. </p>
<div class="footnotes"><p id="fn-d16725e281"><sup><a href="#fnbck-d16725e281">7</a></sup><sup></sup> Nuovo testo giusta la cifra I dell’O del DEFR del 13 nov. 2025, in vigore dal  15 gen. 2026 (<a href="https://fedlex.data.admin.ch/eli/oc/2025/727" target="_blank">RU <b>2025</b> 727</a>).</p></div>
</div></article><article id="art_9"><a name="a9"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_9"><b>Art. 9</b><b></b> <b></b>Basi di calcolo</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4"><sup>1</sup> Helvecura stabilisce il quantitativo di scorte obbligatorie in proporzione al volume di merci che il proprietario ha immesso in commercio nel territorio svizzero nell’anno civile precedente.</p>
<p class="absatz man-space-before-4"><sup>2</sup> In casi motivati, per stabilire il quantitativo di scorte obbligatorie si può fare riferimento al quantitativo medio immesso in commercio nei tre anni civili precedenti, al consumo netto dell’anno civile in corso stimato sull’intero anno o allo smercio previsto per l’anno civile in corso.</p>
<p class="absatz man-space-before-4"><sup>3</sup> Helvecura registra i quantitativi di merci immessi in commercio dalla ditta produttrice e dalle società commerciali almeno ogni trimestre.</p>
<p class="absatz man-space-before-4"><sup>4</sup> Helvecura stabilisce almeno ogni dodici mesi i quantitativi di scorte obbligatorie.</p>
</div></article><article id="art_10"><a name="a10"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_10"><b>Art. 10</b> Mancato raggiungimento del quantitativo di scorte obbligatorie</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4"><sup>1</sup> Per superare improvvise crisi di approvvigionamento l’UFAE può autorizzare temporaneamente valori inferiori del 20 per cento al massimo rispetto al quantitativo totale per gruppo di merci di cui agli articoli 4–7.</p>
<p class="absatz man-space-before-4"><sup>2</sup> Su richiesta e dopo aver consultato Helvecura, l’UFAE può autorizzare in via eccezionale valori temporaneamente inferiori al quantitativo previsto per un proprietario di scorte obbligatorie.</p>
<p class="absatz man-space-before-4"><sup>3</sup> Il contratto per la costituzione di scorte obbligatorie è adeguato di conseguenza.</p>
</div></article><article id="art_11"><a name="a11"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_11"><b>Art. 11</b> Costituzione di scorte obbligatorie da parte di terzi e in comune </a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4"><sup>1</sup> I proprietari di scorte obbligatorie possono ricorrere alla costituzione di scorte obbligatorie da parte di terzi o in comune per una parte o per il totale dei propri quantitativi.<sup><a href="#fn-d16725e355" id="fnbck-d16725e355">8</a></sup></p>
<p class="absatz man-space-before-4"><sup>2</sup> La fondazione e l’organizzazione di una società per la costituzione di scorte obbligatorie in comune richiedono l’approvazione dell’UFAE.</p>
<div class="footnotes"><p id="fn-d16725e355"><sup><a href="#fnbck-d16725e355">8</a></sup><sup></sup> Nuovo testo giusta la cifra I dell’O del DEFR del 13 nov. 2025, in vigore dal  15 gen. 2026 (<a href="https://fedlex.data.admin.ch/eli/oc/2025/727" target="_blank">RU <b>2025</b> 727</a>).</p></div>
</div></article><article id="art_12"><a name="a12"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_12"><b>Art. 12</b> Esecuzione dell’ordinanza e modifica dell’allegato</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4"><sup>1</sup> L’UFAE esegue la presente ordinanza.</p>
<p class="absatz man-space-before-4"><sup>2</sup> L’UFAE può modificare gli allegati dopo aver consultato il settore Agenti terapeutici e Helvecura.</p>
</div></article><article id="art_13"><a name="a13"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_13"><b>Art. 13</b> Entrata in vigore </a>
</h6>
<div class="collapseable"><p class="absatz man-space-before-4">La presente ordinanza entra in vigore il 1° luglio 2019.</p></div></article></main><div id="annex">
<section id="annex_1"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_1">Allegato 1</a><span class="man-font-style-normal"><sup><a href="#fn-d16725e401" id="fnbck-d16725e401">9</a></sup></span>
</h1>
<div class="footnotes"><p id="fn-d16725e401"><sup><a href="#fnbck-d16725e401">9</a></sup><sup></sup> Aggiornato dalle cifre II delle O del DEFR del 4 dic. 2019 (<a href="https://fedlex.data.admin.ch/eli/oc/2019/782" target="_blank">RU <b>2019</b> 4759</a>), del  24 nov. 2023 (<a href="https://fedlex.data.admin.ch/eli/oc/2023/801" target="_blank">RU <b>2023</b> 801</a>) e del 13 nov. 2025, in vigore dal 15 gen. 2026  (<a href="https://fedlex.data.admin.ch/eli/oc/2025/727" target="_blank">RU <b>2025</b> 727</a>).</p></div>
<div class="collapseable">
<p class="titelanhtext">(art. 1)</p>
<section id="annex_1/lvl_u1"><h2 class="heading" role="heading" aria-level="2">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_1/lvl_u1">Merci secondo l’articolo 1</a>
</h2>
<div class="collapseable">
<section id="annex_1/lvl_u1/lvl_1"><h3 class="heading" role="heading" aria-level="3">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_1/lvl_u1/lvl_1">1. Antinfettivi della medicina umana pronti all’uso</a>
</h3>
<div class="collapseable">
<p></p>
<div class="table"><table border="1">
			
			
			<tr>
				
				
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Codice ATC<sup><sup><a href="#fn-d16725e444" id="fnbck-d16725e444">10</a></sup></sup></p>
				</th>
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Designazione della merce</p>
				</th>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr-fett man-font-weight-bold man-space-before-4"><span class="man-font-weight-normal">A07A</span></p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr-fett man-font-weight-bold man-space-before-4"><span class="man-font-weight-normal">antinfettivi intestinali</span></p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J01A</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">tetraciclina</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J01C</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">antibiotici beta-lattamici, penicillina</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J01D</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">altri antibiotici beta-lattamici</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J01E</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">sulfonamidi e trimetoprim</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J01F</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">macrolidi, lincosamidi e streptogramine</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J01G</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">aminoglicosidi</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J01M</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">chinolone</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J01X</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">altri antibiotici</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J02A</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">antimicotici per uso sistemico</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J04A</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">farmaci antitubercolari</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J06BA02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">immunoglobuline umane normali, per somministrazione intravascolare</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J06BB01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">immunoglobulina anti-D (rh)</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J06BB02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">immunoglobulina antitetanica</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J06BB04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">immunoglobulina antiepatite B</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J06BB05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">immunoglobulina antirabica</p>
				</td>
			</tr>
			
		</table></div>
<div class="footnotes"><p id="fn-d16725e444"><sup><a href="#fnbck-d16725e444">10</a></sup><sup></sup> Il codice ATC (<i>Anatomical Therapeutic Chemical Classification System</i>)<i> </i>può essere  consultato in inglese (versione ufficiale) sul sito dell’OMS (<i>WHO Collaborating Centre for Drug Statistics Methodology</i>), all’indirizzo: <a href="http://www.whocc.no" target="_blank">
				www.whocc.no
			</a> &gt; ATC/DDD Index.</p></div>
</div></section><section id="annex_1/lvl_u1/lvl_2"><h3 class="heading" role="heading" aria-level="3">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_1/lvl_u1/lvl_2">2. Principi attivi antinfettivi della medicina umana</a>
</h3>
<div class="collapseable">
<p></p>
<div class="table"><table border="1">
			
			
			<tr>
				
				
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Codice ATC </p>
				</th>
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Designazione della merce</p>
				</th>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4">J01AA02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4">doxiciclina</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J01DD04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">ceftriaxone</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J01GB03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">gentamicina</p>
				</td>
			</tr>
			
		</table></div>
</div></section><section id="annex_1/lvl_u1/lvl_3"><h3 class="heading" role="heading" aria-level="3">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_1/lvl_u1/lvl_3">3. Inibitori della neuraminidasi della medicina umana</a>
</h3>
<div class="collapseable">
<p></p>
<div class="table"><table border="1">
			
			
			<tr>
				
				
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Codice ATC</p>
				</th>
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Designazione della merce</p>
				</th>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4">J05AH02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4">oseltamivir (principio attivo)</p>
				</td>
			</tr>
			
		</table></div>
</div></section><section id="annex_1/lvl_u1/lvl_4"><h3 class="heading" role="heading" aria-level="3">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_1/lvl_u1/lvl_4">4. Analgesici della medicina umana</a>
</h3>
<div class="collapseable">
<p></p>
<div class="table"><table border="1">
			
			
			<tr>
				
				
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Codice ATC</p>
				</th>
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Designazione della merce</p>
				</th>
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Osservazioni</p>
				</th>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4">N01AH06</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4">remifentanil</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">N02AA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">morfina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">N02AA03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">idromorfone </p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">N02AA05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">ossicodone</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">N02AA55</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">combinazioni tra ossicodone e naloxone</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">N02AB03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">fentanile</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">N02AE01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">buprenorfina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">N02BA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">acido acetilsalicilico, incl. acetilsalicilato di lisina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">N07BC02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">metadone</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-after-3">N07BC05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-after-3">levometadone</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-after-3"></p>
				</td>
			</tr>
			
		</table></div>
</div></section><section id="annex_1/lvl_u1/lvl_5"><h3 class="heading" role="heading" aria-level="3">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_1/lvl_u1/lvl_5">5. Vaccini della medicina umana</a>
</h3>
<div class="collapseable">
<p></p>
<div class="table"><table border="1">
			
			
			<tr>
				
				
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Codice ATC</p>
				</th>
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Designazione della merce</p>
				</th>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4">J07AG</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4">vaccino contro l’Haemophilus influenzae di tipo B</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J07AH07</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">meningococco C, antigene polisaccaridico purificato, coniugato</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J07AH08</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">meningococco A, C, Y, W-135, antigene <br>polisaccaridico tetravalente coniugato e purificato</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J07AJ</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">vaccino contro la pertosse</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J07AL02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">pneumococco, antigene polisaccaridico purificato, coniugato</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J07AM</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">vaccino contro il tetano</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J07BA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">vaccino contro la meningoencefalite da zecche, a virus intero inattivato</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J07BC</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">vaccino contro l’epatite</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J07BD</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">vaccino contro il morbillo</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J07BF</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">vaccino contro la poliomielite <br>(combinazioni con Di Ter-Per o Hib, vedere J07CA)</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4">J07BG</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4">vaccino contro la rabbia</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J07BK01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">vaccino contro la varicella, vivo attenuato</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J07BM</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">vaccino contro il virus del papilloma umano</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">J07CA</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">vaccini virali e batterici combinati</p>
				</td>
			</tr>
			
		</table></div>
</div></section><section id="annex_1/lvl_u1/lvl_5_a"><h3 class="heading" role="heading" aria-level="3">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_1/lvl_u1/lvl_5_a">5<span class="man-font-weight-normal"><i>a</i></span><i></i> <i>.</i>Medicamenti oncologici della medicina umana</a>
</h3>
<div class="collapseable">
<p></p>
<div class="table"><table border="1">
			
			
			<tr>
				
				
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Codice ATC</p>
				</th>
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Designazione della merce</p>
				</th>
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Osservazioni</p>
				</th>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4">L01AA03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4">melfalan</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">L01BA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">metotrexato</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">forme parenterali </p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">L01BB03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">tioguanina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">L01BC01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">citarabina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">L01BC05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">gemcitabina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">L01CB01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">etoposide</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">L01CE02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">irinotecano</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">vecchio codice ATC: L01XX19</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">L01DB01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">doxorubicina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">non liposomiale</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">L01XA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">cisplatino</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">L01XA02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">carboplatino</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">L01XA03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">oxaliplatino</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">L02BA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">tamoxifene</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-after-3">L03AX03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-after-3">vaccino BCG</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-after-3"></p>
				</td>
			</tr>
		</table></div>
</div></section><section id="annex_1/lvl_u1/lvl_5_b"><h3 class="heading" role="heading" aria-level="3">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_1/lvl_u1/lvl_5_b">5<span class="man-font-weight-normal"><i>b</i></span><i></i> <i>.</i>Altri medicamenti della medicina umana</a>
</h3>
<div class="collapseable">
<p></p>
<div class="table"><table border="1">
			
			
			<tr>
				
				
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Codice ATC</p>
				</th>
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Designazione della merce</p>
				</th>
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Osservazioni</p>
				</th>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4">B01AD02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4">alteplasi</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4">dosaggio &gt; 2 mg</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">C01CA03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">noradrenalina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">C01CA07</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">dobutamina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">C01CA24</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">adrenalina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">autoiniettori</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">C03CA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">furosemide</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">C07AB02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">metoprololo</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">C07AG01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">labetalolo</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">H01BB02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">ossitocina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">H02AB01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">betametasone</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">forme perorali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">H02AB09</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">idrocortisone</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">forme perorali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">M03AC09</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">rocuronio bromuro</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">N01AX10</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">propofol</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">N05BA06</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">lorazepam</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr">V08BA</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">mezzi di contrasto radiografici contenenti solfato di bario</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-after-3">V08DA</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-after-3">mezzi di contrasto per ultrasonologia</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-after-3"></p>
				</td>
			</tr>
			
		</table></div>
</div></section><section id="annex_1/lvl_u1/lvl_6"><h3 class="heading" role="heading" aria-level="3">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_1/lvl_u1/lvl_6">6. Antinfettivi della medicina veterinaria</a>
</h3>
<div class="collapseable">
<p></p>
<div class="table"><table border="1">
			
			
			<tr>
				
				
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Codice ATCve*t</p>
				</th>
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3"></p>
				</th>
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Designazione della merce</p>
				</th>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4">QA07A</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4">QA07AA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4">neomicina</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">QA07AA10</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">colistina</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">QA07AA51</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">neomicina, combinazioni</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">QA07AB03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">sulfaguanidina</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">QA07AB20</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">sulfonamide, combinazioni</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">QG51A</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">QG51AA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">ossitetraciclina</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">QG51AA02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">tetraciclina</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">QG51AA04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">gentamicina</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">QG51AA05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">cefapirina</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">QJ01A</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">tetraciclina</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">QJ01B</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">amfenicoli</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">QJ01C</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">antibiotici beta-lattamici, penicillina</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">QJ01D</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">altri antibiotici beta-lattamici</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">QJ01E</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">sulfonamidi e trimetoprima</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">QJ01F</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">macrolidi e lincosamidi</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">QJ01G</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">aminoglicosidi</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">QJ01M</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">chinoloni</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">QJ01R</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">combinazioni di antibiotici e/o chemioterapici</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">QJ01X</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">QJ01XQ01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">tiamulina</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">QJ01XQ02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">valnemulina</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">QJ51C</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">antibiotici beta-lattamici, penicillina per uso intramammario</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr">QJ51D</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr"></p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr">altri antibiotici beta-lattamici per uso intramammario</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr man-space-after-3">QJ51R</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-after-3"></p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-after-3">combinazioni di antibiotici per uso intramammario</p>
				</td>
			</tr>
			<tr>
				
				<td colspan="3"><dl class="man-space-after-0">
<dt class="man-space-after-3">* </dt>
<dd class="man-space-after-3">Il codice ATCvet (<i>Anatomical Therapeutic Chemical Classification system for veterinary medicinal products</i>) può essere consultato in inglese (versione ufficiale) sul sito dell’OMS (WHO <i>Collaborating Centre for Drug Statistics Methodology</i>) all’indirizzo seguente: <a href="https://www.whocc.no/atcvet/atcvet_index/" target="_blank">
							www.whocc.no/ATCvet
						</a> &gt; ATCvet Index.</dd>
</dl></td>
			</tr>
		</table></div>
</div></section>
</div></section>
</div></section><section id="annex_2"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_2">Allegato 2</a><span class="man-font-style-normal"><sup><a href="#fn-d16725e2447" id="fnbck-d16725e2447">11</a></sup></span>
</h1>
<div class="footnotes"><p id="fn-d16725e2447"><sup><a href="#fnbck-d16725e2447">11</a></sup><sup></sup> Aggiornato dalla cifra II dell’O del DEFR del 24 nov. 2023, in vigore dal 15 gen. 2024  (<a href="https://fedlex.data.admin.ch/eli/oc/2023/801" target="_blank">RU <b>2023</b> 801</a>).</p></div>
<div class="collapseable">
<p class="titelanhtext">(art. 2)</p>
<section id="annex_2/lvl_u1"><h2 class="heading" role="heading" aria-level="2">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_2/lvl_u1">Esonero dall’obbligo di concludere un contratto per la costituzione di scorte obbligatorie</a>
</h2>
<div class="collapseable">
<section id="annex_2/lvl_u1/lvl_1"><h3 class="heading" role="heading" aria-level="3">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_2/lvl_u1/lvl_1">1. Medicamenti per la medicina umana pronti all’uso</a>
</h3>
<div class="collapseable">
<p class="absatz man-space-before-4">Può essere esonerato dall’obbligo di concludere un contratto per la costituzione di scorte obbligatorie chi, per anno civile, immette in commercio quantitativi inferiori a 5000 dosi giornaliere<sup><a href="#fn-d16725e2470" id="fnbck-d16725e2470">12</a></sup> di un prodotto (totale di tutti i dosaggi e di tutte le forme galeniche).</p>
<div class="footnotes"><p id="fn-d16725e2470"><sup><a href="#fnbck-d16725e2470">12</a></sup><sup></sup>  La dose definita giornaliera è la <i>defined daily dose (DDD) </i>pubblicata dall’OMS. Può essere consultata sul sito dell’OMS (WHO Collaborating Centre for Drug Statistics  Methodology) all’indirizzo <a href="http://www.whocc.no" target="_blank">
				www.whocc.no
			</a> &gt; ATC/DDD Index.</p></div>
</div></section><section id="annex_2/lvl_u1/lvl_2"><h3 class="heading" role="heading" aria-level="3">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_2/lvl_u1/lvl_2">2. Antinfettivi della medicina veterinaria</a>
</h3>
<div class="collapseable">
<p class="absatz man-space-before-4">Può essere esonerato dall’obbligo di concludere un contratto per la costituzione di scorte obbligatorie chi, per anno civile, immette in commercio quantitativi di principi attivi inferiori ai limiti sotto indicati:</p>
<p></p>
<div class="table"><table border="1">
			
			
			<tr>
				
				
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3 man-text-align-right">Forma       </p>
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3"><br>Gruppo di principi attivi</p>
				</th>
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Trattamento di singoli animali</p>
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">chilogrammi</p>
				</th>
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Trattamento di allevamento (premiscela di medicamenti)</p>
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">chilogrammi</p>
				</th>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4">1000/2000 – beta-lattamici</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4 man-text-align-center">50</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4 man-text-align-center">200</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4">         3000 – cloramfenicolo</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4 man-text-align-center">20</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4 man-text-align-center">–</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4">         4000 – tetraciclina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4 man-text-align-center">20</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4 man-text-align-center">200</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4">         5000 – macrolidi</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4 man-text-align-center">10</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4 man-text-align-center">200</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4">      9XXX – altri antibiotici</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4 man-text-align-center">10</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4 man-text-align-center">25</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4">         9500 – aminoglicosidi</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4 man-text-align-center">5</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4 man-text-align-center">25</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4">         9900 – chinolone</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4 man-text-align-center">50</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-4 man-text-align-center">25</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p class="man-template-tab-krpr man-space-after-3">       11000 – sulfonamidi / trimetoprima</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-after-3 man-text-align-center">10</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-after-3 man-text-align-center">25</p>
				</td>
			</tr>
		</table></div>
<p class="abstand1seite man-space-before-0"></p>
</div></section>
</div></section>
</div></section>
</div>
</div></body>
</html>
